Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07057154

Glycated Hbg Index and RDW as Prognstic Indicator in Critical Ill Patients

Glycatetd Hemoglobin Index and Red Cell Distribution Width as Prognstic Indicator in Critical Ill Patients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
97 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers

Summary

The aim of this study was to evaluate the impact of GHI and RDW as prognostic indicator in critically ill Patients.

Detailed description

Primary (Main): determine the levels of the GHI And RDW In Critically Ill Patients at Critical and intermediate care units. b. Secondary (Subsidiary): Evaluate the prognostic significance of these parameters on patient outcomes, such as overall survival, progression-free survival, response to treatment.

Conditions

Interventions

TypeNameDescription
DEVICEHbg and RDWHbg and RDW as prognstic indicator in critical ill patients

Timeline

Start date
2025-07-05
Primary completion
2026-08-29
Completion
2026-12-02
First posted
2025-07-09
Last updated
2025-07-09

Source: ClinicalTrials.gov record NCT07057154. Inclusion in this directory is not an endorsement.

Glycated Hbg Index and RDW as Prognstic Indicator in Critical Ill Patients (NCT07057154) · Clinical Trials Directory